GlaxoSmithKline and AFFiRiS : exclusive licence and option agreement for therapeutic Alzheimer’s disease candidate vaccines

23 October 2008 - GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programmes, aimed at treating Alzheimer’s by targeting beta-amyloid.

As part of the agreement, GSK is acquiring exclusive rights to develop and commercialise two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and are currently in Phase I clinical development. AFFiRiS is also granting GSK an exclusive option to develop and commercialise alternative Alzheimer’s disease vaccine candidates which are in preclinical development... GlaxoSmithKline's Press Release - [PDF] AFFiRiS' Press Release -

EPIX Pharmaceuticals : 2008 Alzheimer's Association International Conference on Alzheimer's Disease

Jul 24, 2008 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it is scheduled to make two presentations at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease in Chicago...


...In May 2008, EPIX announced the initiation of a Phase 2b proof-of-concept program for PRX-03140 that consists of two clinical trials - a six-month trial evaluating PRX-03140 in combination with donepezil and a three-month trial studying PRX-03140 as monotherapy. PRX-03140 is part of EPIX's strategic collaboration with GlaxoSmithKline, which is conducted through GSK's Center of Excellence for External Drug Discovery (CEEDD)... EPIX Pharmaceuticals' Press Release -

EPIX Pharmaceuticals : Phase 2a Alzheimer's Data at Keystone Symposia

March 25, 2008--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that Tom Megerian, M.D., Ph.D, executive director, clinical research of EPIX, is scheduled to present an oral presentation entitled "Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer's Disease" at the Keystone Symposia Alzheimer's Disease Meeting in Keystone, Colorado on Friday, March 28, 2008 at 8:00 a.m. MDT.

EPIX previously announced the compelling results of a Phase 2a clinical trial of PRX-03140 as a single agent and in combination with Aricept(R) in patients with mild Alzheimer's disease. Dr. Megerian's presentation will focus on these previously reported data.

PRX-03140 is part of EPIX's strategic partnership with GlaxoSmithKline... EPIX's Press Release -

GlaxoSmithKline, neuroscience pipeline with compound 742457 for Alzheimer’s disease

Thursday 13 December 2007 - ...742457 — A novel treatment to delay the symptoms of Alzheimer’s disease : Alzheimer’s disease is a devastating neurological condition, with significant consequences on the quality of life for sufferers and their care givers. GSK has a broad programme of research ongoing in Alzheimer’s disease, including 742457, a novel treatment that selectively targets the 5HT6 receptors concentrated within the brain. These receptors are associated with learning and memory... GSK's Press Release -